The Cooper Companies, Inc. operates as a medical device company worldwide. It operates through two segments, CooperVision and CooperSurgical. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia. It also provides range of products and services for enhancing health of women, babies, and families, including medical devices, fertility, genomics, and diagnostics and contraception for hospitals and surgical centers, obstetricians' and gynecologists' (OB/GYNs) medical offices, and fertility clinics. In addition, the company develops mechanical surgical solutions for skin closure; and offers PARAGARD, a contraceptive, as well as provides assisted reproductive technology products, genetic screening and testing, and products within the general OB/GYN offerings. It markets its products under Biofinity, clariti 1day, MyDay, Avaira Vitality, and Proclear 1 Day brand name through a network of field sales representatives, independent agents, eye care practitioners, and distributors. The Cooper Companies, Inc. was founded in 1980 and is headquartered in San Ramon, California.
IPO Year:
Exchange: NYSE
Website: coopercos.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/29/2024 | $115.00 → $120.00 | Overweight | Piper Sandler |
| 7/16/2024 | $107.00 → $115.00 | Hold → Buy | Jefferies |
| 3/19/2024 | $125.00 | Neutral → Buy | Redburn Atlantic |
| 3/13/2024 | $100.00 → $120.00 | Neutral → Overweight | JP Morgan |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/30/2023 | $380.00 | Buy | BofA Securities |
| 10/5/2023 | $390.00 → $343.00 | Overweight → Neutral | Redburn Atlantic |
| 5/30/2023 | $410.00 | Equal-Weight | Morgan Stanley |
| 12/22/2022 | $375.00 | Buy | Mizuho |
| 11/30/2022 | $345.00 → $375.00 | Neutral → Outperform | Robert W. Baird |
SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2026064. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates thr
SAN RAMON, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that the company has been recognized as a Best Workplace for Innovators by Fast Company—a leading business media brand with an editorial focus on innovation—for creating a culture of employee development and belonging that inspires innovation and the development of new products and advocacy initiatives that aim to improve standard-of-care. This prestigious award recognizes organizations from around the world and across a variety of industries that demonstrate a commitment to encouraging and developing innovation at all levels. "Our work matters to us; you can see it in our culture and eve
The simplified insertion process is a milestone innovation for the market's leading hormone-free contraceptive, with an efficacy rate greater than 99% 1,2 CooperSurgical, a global leader in women's healthcare, today announced the launch of a new inserter designed for single-hand placement of Paragard®, which was recently approved by the U.S. Food and Drug Administration (FDA). The new single-hand inserter simplifies the placement process for healthcare providers, making Paragard an even more accessible contraceptive choice for both providers and patients. Paragard, the #1 prescribed copper intrauterine device (IUD), is a tried and true, non-hormonal contraceptive option with more than 30
SAN RAMON, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2024. Revenue increased 8% year-over-year to $1,002.8 million. CooperVision (CVI) revenue up 7% to $675.6 million, and CooperSurgical (CSI) revenue up 9% to $327.2 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.09 or 22% from last year's third quarter.Non-GAAP diluted EPS of $0.96, up $0.12 or 14% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Our
SAN RAMON, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced its participation in the following upcoming investor conferences: 2024 Wells Fargo Healthcare ConferenceWednesday, September 4, 2024, at 3:45 pm ETAl White, President & Chief Executive Officer, will represent the Company in a fireside chat Morgan Stanley Annual Global Healthcare Conference Thursday, September 5, 2024, at 1:50 pm ETAl White, President & Chief Executive Officer, will represent the Company in a fireside chat A webcast of each session will be available to investors and other interested parties by accessing the CooperCompanie
SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7528310. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two busine
SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100 million. The products being acquired generated approximately $14.5 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper's non-GAAP earnings per share in fiscal 2024 and accretive thereafter. "This acquisition is a great st
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
SAN RAMON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2024. Revenue increased 7% year-over-year to $942.6 million. CooperVision (CVI) revenue up 8% to $635.9 million, and CooperSurgical (CSI) revenue up 6% to $306.7 million.GAAP diluted earnings per share (EPS) of $0.44, up $0.24 or 122% from last year's second quarter.Non-GAAP diluted EPS of $0.85, up $0.08 or 10% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White,
SAN RAMON, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today released its 2023 Environmental, Social, and Governance (ESG) Report. The report showcases the company's progress on enhancing the health and wellness of people around the world, while doing its part to protect the planet and serve its communities. In 2023, CooperCompanies continued to make its leading healthcare solutions more accessible in underserved communities, made significant investments in learning and development programs for global employees, and maintained its commitment to protect the planet. "We are most innovative when we leverage synergies across our ESG priorities," said Al White, Coope
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
4 - COOPER COMPANIES, INC. (0000711404) (Issuer)
SAN RAMON, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2024 financial results on Thursday, December 5, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 2026064. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates thr
SAN RAMON, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal third quarter ended July 31, 2024. Revenue increased 8% year-over-year to $1,002.8 million. CooperVision (CVI) revenue up 7% to $675.6 million, and CooperSurgical (CSI) revenue up 9% to $327.2 million.GAAP diluted earnings per share (EPS) of $0.52, up $0.09 or 22% from last year's third quarter.Non-GAAP diluted EPS of $0.96, up $0.12 or 14% from last year's third quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "Our
SAN RAMON, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report third quarter 2024 financial results on Wednesday, August 28, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 7528310. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two busine
SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100 million. The products being acquired generated approximately $14.5 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper's non-GAAP earnings per share in fiscal 2024 and accretive thereafter. "This acquisition is a great st
SAN RAMON, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2024. Revenue increased 7% year-over-year to $942.6 million. CooperVision (CVI) revenue up 8% to $635.9 million, and CooperSurgical (CSI) revenue up 6% to $306.7 million.GAAP diluted earnings per share (EPS) of $0.44, up $0.24 or 122% from last year's second quarter.Non-GAAP diluted EPS of $0.85, up $0.08 or 10% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White,
SAN RAMON, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report second quarter 2024 financial results on Thursday, May 30, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1712676. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two
SAN RAMON, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal first quarter ended January 31, 2024. Revenue increased 9% year-over-year to $931.6 million. CooperVision (CVI) revenue up 7% to $621.5 million, and CooperSurgical (CSI) revenue up 12% to $310.1 million.GAAP diluted earnings per share (EPS) of $0.41, down $0.02 or 5% from last year's first quarter.Non-GAAP diluted EPS of $0.85, up $0.12 or 18% from last year's first quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, Cooper's President and CEO said, "W
SAN RAMON, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report first quarter 2024 financial results on Thursday, February 29, 2024, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 5337119. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two b
SAN RAMON, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal fourth quarter and full year ended October 31, 2023. Fourth quarter 2023 revenue of $927.1 million, up 9%, and up 9% organically. Fiscal year 2023 revenue of $3.6 billion, up 9%, or up 10% organically.Fourth quarter 2023 GAAP diluted earnings per share (EPS) of $1.70, up 29%. Fiscal 2023 GAAP diluted EPS of $5.91, down 24%.Fourth quarter 2023 non-GAAP diluted EPS of $3.47, up 26%. Fiscal 2023 non-GAAP diluted EPS of $12.81, up 3%. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on t
SAN RAMON, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) today announced it will report fourth quarter and full year 2023 financial results on Thursday, December 7, 2023, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3206652. A simultaneous audio webcast can be accessed on CooperCompanies' investor relations website at http://investor.coopercos.com. A replay of the event will be available on the same webpage following its conclusion. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
SD - COOPER COMPANIES, INC. (0000711404) (Filer)
10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
8-K - COOPER COMPANIES, INC. (0000711404) (Filer)
DEFA14A - COOPER COMPANIES, INC. (0000711404) (Filer)
Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously
Jefferies upgraded Cooper from Hold to Buy and set a new price target of $115.00 from $107.00 previously
Redburn Atlantic upgraded Cooper from Neutral to Buy and set a new price target of $125.00
JP Morgan upgraded Cooper from Neutral to Overweight and set a new price target of $120.00 from $100.00 previously
KeyBanc Capital Markets resumed coverage of Cooper with a rating of Sector Weight
BofA Securities initiated coverage of Cooper with a rating of Buy and set a new price target of $380.00
Redburn Atlantic downgraded Cooper from Overweight to Neutral and set a new price target of $343.00 from $390.00 previously
Morgan Stanley initiated coverage of Cooper with a rating of Equal-Weight and set a new price target of $410.00
Mizuho initiated coverage of Cooper with a rating of Buy and set a new price target of $375.00
Robert W. Baird upgraded Cooper from Neutral to Outperform and set a new price target of $375.00 from $345.00 previously
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)
Jefferies analyst Young Li upgrades Cooper Companies (NASDAQ:COO) from Hold to Buy and raises the price target from $107 to $115.
Piper Sandler analyst Jason Bednar maintains Cooper Companies (NASDAQ:COO) with a Overweight and maintains $115 price target.
Bears knocked on Wall Street’s door again Friday, sending large-cap tech stocks lower despite the Fed’s favorite inflation measure meeting expectations. Both the S&P 500 and the Nasdaq 100 index are set to end a 5-week winning streak as investors grow more cautious about the latest economic developments. In April 2024, the Personal Consumption Expenditure (PCE) price index held steady at 2.7% year-on-year, matching the previous month and forecasts. The annual core inflation rate also remained unchanged at 2.8%, in line with expectations. However, concerns arose from a deceleration in personal spending and income, raising fears that strong consumer momentum is waning. Additionally, t
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. (NASDAQ:AMBA) rose sharply during Friday's session following strong first-quarter earnings and upbeat second-quarter guidance. Ambarella posted adjusted loss of 26 cents per share, compared to market estimates for a loss of 31 cents per share. The company's quarterly sales came in at $54.473 million beating expectations of $53.875 million, according to data from Benzinga Pro. Ambarella shares jumped 23% to $59.42 on Friday. Here are some other big stocks recording gains in today's session. Latam Logistic Properties, S.A. (NYSE:LPA) shares jumped 79.5% to $464.77. The Ga
Baird analyst Jeff Johnson maintains Cooper Companies (NASDAQ:COO) with a Outperform and raises the price target from $116 to $118.
Stocks look set to end May on a positive note, even as index futures pointed to a negative opening on Friday. But sentiment could reverse if important inflation data due ahead of the market open appeases Wall Street. The inflation data assumes importance as it could have a bearing on the June 11-12 Federal Reserve’s rate-setting meeting, with the May consumer price inflation report due only on May 12. Reactions to earnings, especially from the tech and retail spaces, have been mixed. FuturesPerformance (+/-)Nasdaq 100-0.48%S&P 500-0.31%Dow-0.15%R2K-0.57% In premarket trading on Friday, the SPDR S&P 500 ETF Trust (NYSE:SPY) fell 0.26% to $521.27, and the Invesco QQQ ETF (NASDAQ:QQQ) tra
Needham analyst David Saxon reiterates Cooper Companies (NASDAQ:COO) with a Hold.
Cooper Companies (NYSE:COO) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.83 by 2.41 percent. The company reported quarterly sales of $942.60 million which missed the analyst consensus estimate of $948.06 million by 0.58 percent. This is a 7.43 percent increase over sales of $877.40 million the same period last year.
Wall Street experienced another decline on Thursday, with major large-cap indices affected by a downturn in the tech and communication services sectors. Investors shifted their focus to market areas that have underperformed compared to tech over the past year, such as small caps, real estate and solar stocks. In economic news, the second estimate of first-quarter GDP growth was revised down to 1.3% from the initial 1.6% estimate, driven by slower consumer spending growth. Inflation also saw a slight decrease. New York Fed President John Williams stated there is no immediate need to adjust monetary policy and expects inflation to continue its decline, reaching the 2% target by 2025.
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo
SAN RAMON, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that its Board of Directors has appointed Cynthia Lucchese as an independent director, effective October 1, 2022. Lucchese has also been appointed to serve on the Audit Committee and Corporate Governance and Nominating Committee when she joins the Board. "We are pleased to welcome Cindy to Cooper's Board of Directors," said Al White, President and CEO of CooperCompanies. "She is a highly successful executive with a strong strategic, financial, and operational background. We are confident that her business acumen and board experiences will benefit Cooper and our shareholders." Lucchese currentl
SAN RAMON, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE:COO) announced today that Nicholas Khadder has been appointed as its general counsel and corporate secretary. Khadder joins Cooper having previously served as general counsel of Standard BioTools Inc. (formerly Fluidigm Corporation) from June 2016 to July 2022. Prior to joining Fluidigm, from 2010 to June 2016, Khadder held various positions at Amyris, Inc., including general counsel and corporate secretary from 2013 to June 2016. Previously, Khadder served in senior corporate counsel roles at LeapFrog Enterprises, Inc. from August 2008 to September 2010, and at Protiviti Inc. (a subsidiary of Robert Half Internati
SAN RAMON, Calif., May 23, 2022 /PRNewswire/ -- CooperVision, one of the world's leading manufacturers of contact lenses, has named Alex Wilkes as President, Americas, effective June 14. Wilkes brings more than a decade of experience in the eye care industry, having most recently served as Senior Vice President and General Manager of Pearle Vision at Luxottica. As CooperVision's Americas President, Wilkes will be responsible for driving the growth of the company's largest region.At CooperVision, Wilkes will be responsible for the executive leadership and driving the growth of
SAN MATEO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Today Veev, the technology-enabled homebuilding company, announced the latest addition to its leadership team, naming Gordon Heneweer as Chief Financial Officer. Heneweer will oversee all finance and accounting functions including the Corporate Controllership, FP&A, project finance, Treasury, Tax and business operations, as well as corporate strategy. Veev has achieved a novel approach to homebuilding that views the home as the ultimate consumer product––a highly personal space that should enhance and reflect the lives of the people who live there. Grounded in this consumer-first focus, Veev has pioneered a breakthrough technological a
Holly Sheffield, Medical Technology Executive and Investment Banker Hank Plain, Serial Entrepreneur, Executive and Venture Capital Leader James Rogers, Public and Private Medical Technology Investor Imperative Care, Inc. today announced three appointments to the company's Board of Directors with the addition of Holly Sheffield, Hank Plain, and James Rogers. "We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts," said Fred Khosravi, Chairman and CEO of Imperative Care. "Having these high-caliber professionals join our Boar
NEW YORK, March 5, 2021 /PRNewswire/ -- TMRW Life Sciences, Inc. ("TMRW"), the creator of the world's first and only automated technology platform for the management, identification, and storage of frozen eggs and embryos, announces today that Brian E. Miller, PhD, is joining TMRW's senior leadership team as Senior Vice President of Sales. In his role, Brian will be responsible for bringing TMRW's innovative technology to fertility clinics in the United States. Brian will also be integral to the ongoing development of new products and services that will expand TMRW's offerings, enabling fertility clinics to further enhance and automate their clinical lab operations. A veteran of the fertilit
SAN RAMON, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO), announced today that consistent with the plan approved by its board of directors to pay annual dividends, the Company declared a semi-annual dividend of 3 cents per share, payable on February 9, 2021, to stockholders of record on January 22, 2021. About CooperCompaniesCooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providin